Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
Summary
- Eligibility
- for people ages 12-120 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Adil Daud
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Adil Daud
Professor, Medicine, School of Medicine. Authored (or co-authored) 188 research publications
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Novartis Pharmaceuticals
- ID
- NCT04417621
- Phase
- Phase 2 research study
- Study Type
- Interventional
- Last Updated